文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

D-PRISM:一项评估重症监护病房肺炎诊断与治疗方法的全球调查研究

D-PRISM: a global survey-based study to assess diagnostic and treatment approaches in pneumonia managed in intensive care.
PubMed 文献 · Crit Care · 2024-11-22
一句话结论全球72国1296名ICU临床医生的调查显示,肺炎诊断流程与抗菌药物疗程差异大,30%(389人)不认为影像学证据是诊断肺炎的必要条件,低收入国家微生物诊断可及性最低。

D-PRISM为多国在线问卷调查,于2022年9月至11月向72个国家的重症监护临床医生发放自填问卷,评估社区获得性肺炎(CAP)、医院获得性肺炎(HAP)和呼吸机相关性肺炎(VAP)的诊断与治疗实践。共回收1296份有效应答,低收入与中等收入国家(LMIC)受访者占51%。诊断流程存在异质性:30%(389人)不认为影像学证据对诊断肺炎必不可少,微生物标本采集与支气管镜使用实践不一,微生物诊断在低收入和中低收入国家可及性最低;所有类型肺炎的意向抗菌疗程众数为5-7天,较短疗程与抗菌药物管理(AMS)项目、高国家收入水平和正式重症监护培训相关。研究提示需要改进对现有指南的依从性并标准化ICU肺炎诊治流程。

要点

  • 在1296名ICU临床医生中,30%(389人)不认为影像学证据是诊断肺炎的必要条件,诊断流程异质性明显。
  • 所有类型肺炎(CAP、HAP、VAP)的意向抗菌治疗疗程众数均为5-7天。
  • 较短抗菌疗程与抗菌药物管理(AMS)项目、高国家收入水平及正式重症监护培训相关。
  • 微生物诊断在低收入和中低收入国家可及性最低,诊断工具获取存在差异。
  • 研究强调需要改进对现有指南的依从性并标准化ICU肺炎诊断与治疗方法。

适用人群与场景

  • 来自72个国家的重症监护临床医生,于2022年9月至11月接受在线自填问卷调查。
  • 受访者分布于低收入与中等收入国家(LMIC)和高收入国家(HIC),LMIC受访者占51%。

处置流程与药物剂量

  • 所有类型肺炎(CAP、HAP、VAP)的意向抗菌治疗疗程众数为5-7天。
  • 较短抗菌疗程与抗菌药物管理(AMS)项目、高国家收入水平及正式重症监护培训相关。

研究设计与关键结果

  • D-PRISM为多国、基于调查的研究,于2022年9月至11月向72个国家的重症监护临床医生发放自填在线问卷,共回收1296份有效应答,LMIC受访者占51%。
  • 30%(389人)的受访者不认为影像学证据是诊断肺炎的必要条件。
  • 微生物标本采集和支气管镜使用与实践存在差异;微生物诊断在低收入和中低收入国家可及性最低。
  • 所有类型肺炎的意向抗菌治疗疗程众数为5-7天。
  • 较短抗菌疗程与AMS项目、高国家收入水平及正式重症监护培训相关(多因素回归分析)。

证据类型、等级与局限

  • 证据类型:多国、基于调查的研究(横断面问卷调查)。
  • 研究未注册,作为当前实践调查,由欧洲重症监护医学会(European Society of Intensive Care Medicine)审查并认可。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 研究提示需要改进对现有指南的依从性,并采用标准化方法诊断和治疗ICU肺炎。
  • 研究强调尤其需要解决低收入和中等收入国家在诊断工具获取方面的问题。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Pneumonia remains a significant global health concern, particularly among those requiring admission to the intensive care unit (ICU). Despite the availability of international guidelines, there remains heterogeneity in clinical management. The D-PRISM study aimed to develop a global overview of how pneumonias (i.e., community-acquired (CAP), hospital-acquired (HAP), and Ventilator-associated pneumonia (VAP)) are diagnosed and treated in the ICU and compare differences in clinical practice worldwide.

METHODS: The D-PRISM study was a multinational, survey-based investigation to assess the diagnosis and treatment of pneumonia in the ICU. A self-administered online questionnaire was distributed to intensive care clinicians from 72 countries between September to November 2022. The questionnaire included sections on professional profiles, current clinical practice in diagnosing and managing CAP, HAP, and VAP, and the availability of microbiology diagnostic tests. Multivariable analysis using multiple regression analysis was used to assess the relationship between reported antibiotic duration and organisational variables collected in the study.

RESULTS: A total of 1296 valid responses were collected from ICU clinicians, spread between low-and-middle income (LMIC) and high-income countries (HIC), with LMIC respondents comprising 51% of respondents. There is heterogeneity across the diagnostic processes, including clinical assessment, where 30% (389) did not consider radiological evidence essential to diagnose pneumonia, variable collection of microbiological samples, and use and practice in bronchoscopy. Microbiological diagnostics were least frequently available in low and lower-middle-income nation settings. Modal intended antibiotic treatment duration was 5-7 days for all types of pneumonia. Shorter durations of antibiotic treatment were associated with antimicrobial stewardship (AMS) programs, high national income status, and formal intensive care training.

CONCLUSIONS: This study highlighted variations in clinical practice and diagnostic capabilities for pneumonia, particularly issues with access to diagnostic tools in LMICs were identified. There is a clear need for improved adherence to existing guidelines and standardized approaches to diagnosing and treating pneumonia in the ICU. Trial registration As a survey of current practice, this study was not registered. It was reviewed and endorsed by the European Society of Intensive Care Medicine.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Reyes LF, Serrano-Mayorga CC, Zhang Z, et al. D-PRISM: a global survey-based study to assess diagnostic and treatment approaches in pneumonia managed in intensive care. Crit Care. 2024. PMID: 39578900. doi:10.1186/s13054-024-05180-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。